The Genetic Information and Family Testing (GIFT) study: trial design and protocol
Open Access
- 27 February 2025
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-16
Abstract
Background: There is pressing need to develop and evaluate clinically sound approaches to supporting the engagement between patients who have inherited cancer susceptibility and their relatives who may share it. Identifying and engaging patients with an inherited cancer susceptibility in the community is a potentially powerful strategy to reduce the gap in genetic risk evaluation for their families. The goal of the Genetic Information and Family Testing (GIFT) Study is to engage patients about inherited cancer susceptibility and provide support and services to their relatives to initiate genetic risk evaluation (including choice of home genetic testing). Methods/design: We are conducting a population-based, 2 × 2 factorial cluster-randomized clinical trial to implement and evaluate a direct-to-family, virtual, personalized, family-centered communication and decision-making tool: the Family Genetic Health Program. We use a unique SEER-based data infrastructure that we pioneered to identify patients diagnosed with cancer in the states of Georgia and California who carry a pathogenic variant (PV) in clinically tested cancer susceptibility gene. Eligible patients are offered enrollment into the trial and can invite their eligible first- and second-degree relatives to enroll. The index subject is randomized, and relatives are then cluster randomized by family. Participants in all arms receive some level of intervention, including at least the web-based platform with information about genetic testing and, for the relatives, an option to receive genetic testing through the study platform. We study the effects of two intervention design features: (1) the level of personalized family genetic risk navigation support: a technology-assisted, personally tailored patient and family member education and communication tool vs. the tool plus direct assistance from a lay human navigator); and (2) the cost of the genetic test offered to the relatives ($50 vs. free). Discussion: GIFT is a blueprint for how a virtual cascade genetic risk program can be delivered in the community, through a population-based approach to patients and relatives in families with hereditary cancer syndromes. The vision, experiences, and findings from GIFT will inform next-generation implementation science and the results will pertain to stakeholders interested in a population-based approach to cascade genetic risk evaluation. Trial registration: NCT05552664 registered at Clincaltrials.gov September 20, 2022.Keywords
Funding Information
- National Cancer Institute (U01CA254822)
- American Cancer Society (RSG-20-025-01)
This publication has 14 references indexed in Scilit:
- Cancer genetic counselling for hereditary breast cancer in the era of precision oncologyCancer Treatment Reviews, 2024
- Only 32.3% of Breast Cancer Families with Pathogenic Variants in Cancer Genes Utilized Cascade Genetic TestingCancers, 2023
- Do people with hereditary cancer syndromes inform their at-risk relatives? A systematic review and meta-analysisPEC Innovation, 2023
- Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer PreventionJCO Precision Oncology, 2021
- Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With Breast Cancer or Ovarian Cancer, 2012-2019Journal of Clinical Oncology, 2021
- Emerging Opportunity of Cascade Genetic Testing for Population-Wide Cancer Prevention and ControlJournal of Clinical Oncology, 2020
- Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based ScreeningJournal of Clinical Oncology, 2020
- Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer preventionGynecologic Oncology, 2020
- Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast CancerJAMA Oncology, 2018
- ACOG Committee Opinion No. 727: Cascade Testing: Testing Women for Known Hereditary Genetic Mutations Associated With CancerObstetrics & Gynecology, 2018